Research Analysts Offer Predictions for SNDX FY2027 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Investment analysts at B. Riley decreased their FY2027 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a report issued on Friday, October 3rd. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of $0.05 for the year, down from their previous forecast of $0.12. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.18. The firm had revenue of $37.96 million for the quarter, compared to analysts’ expectations of $26.64 million. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The company’s quarterly revenue was up 984.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.80) EPS.

Several other analysts have also issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Syndax Pharmaceuticals in a report on Saturday, September 27th. Stifel Nicolaus assumed coverage on Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They issued a “buy” rating and a $44.00 price target on the stock. UBS Group decreased their price target on Syndax Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, July 15th. BTIG Research reaffirmed a “buy” rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a report on Friday, September 19th. Finally, Guggenheim began coverage on shares of Syndax Pharmaceuticals in a report on Thursday, September 4th. They set a “buy” rating and a $34.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.22.

Syndax Pharmaceuticals Stock Up 1.0%

SNDX stock opened at $15.60 on Monday. The company has a debt-to-equity ratio of 2.06, a current ratio of 4.71 and a quick ratio of 4.55. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -4.01 and a beta of 0.68. The business’s fifty day moving average price is $14.61 and its two-hundred day moving average price is $12.16. Syndax Pharmaceuticals has a fifty-two week low of $8.58 and a fifty-two week high of $22.50.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP increased its holdings in Syndax Pharmaceuticals by 77.3% in the second quarter. Hudson Bay Capital Management LP now owns 443,300 shares of the company’s stock worth $4,152,000 after purchasing an additional 193,300 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock worth $79,000 after purchasing an additional 4,308 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in Syndax Pharmaceuticals by 33.7% in the second quarter. Soleus Capital Management L.P. now owns 1,092,110 shares of the company’s stock worth $10,228,000 after purchasing an additional 275,500 shares in the last quarter. Man Group plc increased its holdings in Syndax Pharmaceuticals by 70.1% in the second quarter. Man Group plc now owns 228,167 shares of the company’s stock worth $2,137,000 after purchasing an additional 94,031 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Syndax Pharmaceuticals in the second quarter worth approximately $66,000.

Insider Buying and Selling

In related news, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $16.41, for a total value of $2,581,407.87. Following the transaction, the chief executive officer directly owned 298,661 shares of the company’s stock, valued at $4,901,027.01. The trade was a 34.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dennis Podlesak sold 19,200 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.84, for a total value of $304,128.00. Following the completion of the transaction, the director directly owned 191,763 shares in the company, valued at approximately $3,037,525.92. This represents a 9.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 204,537 shares of company stock worth $3,265,935. 4.10% of the stock is owned by insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).